CNRS UMR7370, LP2M, faculté de médecine, 28, avenue de Valombrose, 06107 Nice cedex 2, France; Université Nice-Sophia-Antipolis, 06100 Nice, France; Department of Pharmacy, Cardenal Herrera-CEU University, 46115 Alfara del Patriarca, València, Spain.
CNRS UMR7370, LP2M, faculté de médecine, 28, avenue de Valombrose, 06107 Nice cedex 2, France; Université Nice-Sophia-Antipolis, 06100 Nice, France.
Joint Bone Spine. 2019 Jan;86(1):43-47. doi: 10.1016/j.jbspin.2018.02.008. Epub 2018 Apr 11.
The gut microbiome is now viewed as a tissue that interacts bidirectionally with the gastrointestinal, immune, endocrine and nervous systems, affecting the cellular responses in numerous organs. Evidence is accumulating of gut microbiome involvement in a growing number of pathophysiological processes, many of which are linked to inflammatory responses. More specifically, data acquired over the last decade point to effects of the gut microbiome on bone mass regulation and on the development of bone diseases (such as osteoporosis) and of inflammatory joint diseases characterized by bone loss. Mice lacking a gut microbiome have bone mass alteration that can be reversed by gut recolonization. Changes in the gut microbiome composition have been reported in mice with estrogen-deficiency osteoporosis and have also been found in a few studies in humans. Probiotic therapy decreases bone loss in estrogen-deficient animals. The effect of the gut microbiome on bone tissue involves complex mechanisms including modulation of CD4T cell activation, control of osteoclastogenic cytokine production and modifications in hormone levels. This complexity may contribute to explain the discrepancies observed betwwen some studies whose results vary depending on the age, gender, genetic background and treatment duration. Further elucidation of the mechanisms involved is needed. However, the available data hold promise that gut microbiome manipulation may prove of interest in the management of bone diseases.
肠道微生物组现在被视为一种与胃肠道、免疫、内分泌和神经系统双向相互作用的组织,影响众多器官的细胞反应。越来越多的病理生理过程涉及肠道微生物组的参与,其中许多与炎症反应有关。更具体地说,过去十年获得的数据表明,肠道微生物组对骨量调节以及骨疾病(如骨质疏松症)和以骨质流失为特征的炎症性关节疾病的发展有影响。缺乏肠道微生物组的小鼠的骨量发生改变,而肠道再定植可以逆转这种改变。雌激素缺乏性骨质疏松症小鼠的肠道微生物组组成发生变化,在少数人类研究中也发现了这种变化。益生菌治疗可减少去势动物的骨丢失。肠道微生物组对骨组织的影响涉及复杂的机制,包括调节 CD4T 细胞的激活、控制破骨细胞生成细胞因子的产生以及激素水平的改变。这种复杂性可能有助于解释一些研究之间存在的差异,这些差异的结果取决于年龄、性别、遗传背景和治疗持续时间。需要进一步阐明所涉及的机制。然而,现有数据表明,肠道微生物组的操纵可能在骨疾病的治疗中具有重要意义。